title: Recombinant hepatitis B virus surface antigen formulated with B-type CpG oligodeoxynucleotide induces therapeutic immunity against hepatitis B virus surface antigen-expressing liver cancer cells in mice.
abstract: To develop a therapeutic vaccine against hepatitis B virus surface antigen (HBsAg)-expressing liver cancer, we tried to prepare a vaccine by formulating recombinant HBsAg with BW006, a B type CpG oligodeoxynucleotide (ODN) with Th1-biasing activity, and examined its potency of inducing therapeutic immunity against HBsAg-expressing liver cancer cells in mice. When applied therapeutically, BW006 could assist HBsAg to induce vigorous immune responses capable of inhibiting the growth of HBsAg-expressing liver cancer cells and prolonging the survival of mice bearing HBsAg-expressing liver cancer cells. In vivo and in vitro experiments showed that the BW006-adjuvanted HBsAg enhanced the production of IgG2a antibodies, interferon-γ, and interleukin-12 and facilitated the generation of specific cytotoxic T lymphocyte that killed the HBsAg-expressing liver cancer cells. These results suggest that the BW006-adjuvanted HBsAg might be developed into a candidate tumor vaccine for the treatment of HBsAg-expressing liver cancer.
authors.affiliation: Department of Molecular Biology, Norman Bethune College of Medicine, Jilin University, Changchun, China.
authors.forename: Xiaojing
authors.initials: X
authors.lastname: Zhou
authors.forename: Hongfei
authors.initials: H
authors.lastname: Wei
authors.forename: Peng
authors.initials: P
authors.lastname: Sun
authors.forename: Xiuli
authors.initials: X
authors.lastname: Wu
authors.forename: Min
authors.initials: M
authors.lastname: Wan
authors.forename: Peng
authors.initials: P
authors.lastname: Zhang
authors.forename: Sheng
authors.initials: S
authors.lastname: Guo
authors.forename: Tiesuo
authors.initials: T
authors.lastname: Zhao
authors.forename: Yongli
authors.initials: Y
authors.lastname: Yu
authors.forename: Liying
authors.initials: L
authors.lastname: Wang
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000276:immunology*; D049109:Cell Proliferation; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007371:Interferon-gamma / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D053208:Kaplan-Meier Estimate; D037181:Lectins, C-Type / Q000378:metabolism; D008113:Liver Neoplasms / Q000188:drug therapy / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009838:Oligodeoxyribonucleotides / Q000276:immunology*; D011994:Recombinant Proteins; D013602:T-Lymphocytes, Cytotoxic; D014407:Tumor Cells, Cultured; D000099192:CD69 Antigens
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D019496:Cancer Vaccines; D006514:Hepatitis B Surface Antigens; D007074:Immunoglobulin G; D007371:Interferon-gamma; D018664:Interleukin-12; D037181:Lectins, C-Type; D009838:Oligodeoxyribonucleotides; D011994:Recombinant Proteins; D000099192:CD69 Antigens